« Previous Next » Epilepsy Research
Volume 83, Issue 1 , Pages 44-51 , January 2009

No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy

J.M. Lynch
- Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
- National Society for Epilepsy, Chalfont-St-Peter, Bucks SL9 0RJ, UK
- These authors contributed equally to this work.
S.K. Tate
- Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
- National Society for Epilepsy, Chalfont-St-Peter, Bucks SL9 0RJ, UK
- These authors contributed equally to this work.
P. Kinirons
- The Department of Clinical Neurological Sciences and Molecular and Cellular Therapeutics, RCSI Research Institute Royal College of Surgeons in Ireland, and Division of Neurology, Beaumont Hospital, Dublin, Ireland
M.E. Weale
- Institute for Genome Sciences and Policy, Center for Population Genomics and Pharmacogenetics, Duke University, 103 Research Drive, Rm 4006 GSRB II, Box 3471 DUMC, Durham, NC 27710, USA
G.L. Cavalleri
- The Department of Clinical Neurological Sciences and Molecular and Cellular Therapeutics, RCSI Research Institute Royal College of Surgeons in Ireland, and Division of Neurology, Beaumont Hospital, Dublin, Ireland
C. Depondt
- Service de Neurologie, Hôpital Erasme, Université Libre de Bruxelles, 808 Route de Lennik, 1070 Brussels, Belgium
K. Murphy
- The Department of Clinical Neurological Sciences and Molecular and Cellular Therapeutics, RCSI Research Institute Royal College of Surgeons in Ireland, and Division of Neurology, Beaumont Hospital, Dublin, Ireland
D. O’Rourke
- The Department of Clinical Neurological Sciences and Molecular and Cellular Therapeutics, RCSI Research Institute Royal College of Surgeons in Ireland, and Division of Neurology, Beaumont Hospital, Dublin, Ireland
C.P. Doherty
- Department of Neurology, St. James’s Hospital, James Street, Dublin 8, Ireland
K.V. Shianna
- Institute for Genome Sciences and Policy, Center for Population Genomics and Pharmacogenetics, Duke University, 103 Research Drive, Rm 4006 GSRB II, Box 3471 DUMC, Durham, NC 27710, USA
N.W. Wood
- Department of Molecular Neuroscience, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
J.W. Sander
- Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
- National Society for Epilepsy, Chalfont-St-Peter, Bucks SL9 0RJ, UK
- SEIN – Epilepsy Institutes of the Netherlands Foundation, Achterweg 5, 2103 SW Heemstede, The Netherlands
N. Delanty
- Department of Neurology, Beaumont Hospital, Dublin 9, Ireland
- Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
D.B. Goldstein
- Institute for Genome Sciences and Policy, Center for Population Genomics and Pharmacogenetics, Duke University, 103 Research Drive, Rm 4006 GSRB II, Box 3471 DUMC, Durham, NC 27710, USA
- These authors jointly supervised this work.
- Corresponding author at: Department of Clinical and Experimental Epilepsy, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK. Tel.: +44 20 3108 0112; fax: +44 20 3108 0115.
S.M. Sisodiya
- Department of Clinical and Experimental Epilepsy, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
- National Society for Epilepsy, Chalfont-St-Peter, Bucks SL9 0RJ, UK
- These authors jointly supervised this work.
- Corresponding author at: Department of Clinical and Experimental Epilepsy, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK. Tel.: +44 20 3108 0112; fax: +44 20 3108 0115.